Global Liver Cancer Therapeutics Market
According to the report " Liver Cancer Therapeutics Market ", published by Market Data Forecast , the global market is projected to reach USD 884.14 million by 2021 , at a CAGR of 9.1 % from 2016 to 2021 .
Treating cancer is still not easy because disease symptoms generally appear in the late stage of the disease , resulting in a low diagnosis rate that in turn disturbs the patient volume available for treatment . Studies on liver cancer therapeutics illustrate that the prevalence of liver cancer is greater in men than in women and is generally seen in people over the age of 50 . Treatment is based on tumour size , location , and overall health .
Increasing number of liver cancer cases all over the globe involves huge amount of drugs for the treatment or prevention of liver cancer and tumours . Further , growing healthcare expenditure and increasing government initiatives are also augmenting the growth of this market . Additionally , high unmet necessities for the treatment of liver cancer also supports in market growth .
The Global Liver Cancer Therapeutics Market is segmented by Type , Therapeutics , End- Users and region .
1 ) By Type :
� � �
Primary Secondary Benign Liver Growths
2 ) By Therapeutics :
� � � �
Hepatocellular Carcinoma Cholangio Carcinoma Hepatoblastoma Targeted Therapy
3 ) By End-Users :
� �
Pediatrics Adults
4 ) By Geography :
� � � � �
North America Europe Asia-Pacific Latin America Middle-East and Africa
Some of the key contributors in the industry include Alnylam Pharmaceuticals Inc ., ImClone Systems Inc ., Onyx Pharmaceuticals Inc ., F . Hoffmann-La Roche Ltd ., Pfizer Inc ., ArQule Inc .,
+ 1 888-702-9626 | www . marketdataforecast . com | contact @ marketdataforecast . com